ATE464304T1 - Carboxamid-spirolactam-cgrp-rezeptor-antagonist n - Google Patents

Carboxamid-spirolactam-cgrp-rezeptor-antagonist n

Info

Publication number
ATE464304T1
ATE464304T1 AT05795301T AT05795301T ATE464304T1 AT E464304 T1 ATE464304 T1 AT E464304T1 AT 05795301 T AT05795301 T AT 05795301T AT 05795301 T AT05795301 T AT 05795301T AT E464304 T1 ATE464304 T1 AT E464304T1
Authority
AT
Austria
Prior art keywords
sup
carboxamide
receptor antagonist
cgrp receptor
compounds
Prior art date
Application number
AT05795301T
Other languages
English (en)
Inventor
Theresa WILLIAMS
Christopher Burgey
Thomas Tucker
Craig Stump
Ian Bell
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE464304T1 publication Critical patent/ATE464304T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05795301T 2004-09-13 2005-09-09 Carboxamid-spirolactam-cgrp-rezeptor-antagonist n ATE464304T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60943604P 2004-09-13 2004-09-13
PCT/US2005/032036 WO2006031606A2 (en) 2004-09-13 2005-09-09 Carboxamide spirolactam cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
ATE464304T1 true ATE464304T1 (de) 2010-04-15

Family

ID=36060551

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05795301T ATE464304T1 (de) 2004-09-13 2005-09-09 Carboxamid-spirolactam-cgrp-rezeptor-antagonist n

Country Status (9)

Country Link
US (1) US7390798B2 (de)
EP (1) EP1796678B1 (de)
JP (1) JP5039553B2 (de)
CN (1) CN101448821B (de)
AT (1) ATE464304T1 (de)
AU (1) AU2005285197B2 (de)
CA (1) CA2579840C (de)
DE (1) DE602005020655D1 (de)
WO (1) WO2006031606A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289448B1 (de) 1999-05-11 2013-03-13 Atrionix, Inc. Gewebeablationssystem mit einem Ballonverankerungsdraht
EP1606286B1 (de) * 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten
JP2008512459A (ja) * 2004-09-09 2008-04-24 メルク エンド カムパニー インコーポレーテッド アリールスピロラクタムcgrp受容体拮抗薬
AU2005285083B2 (en) * 2004-09-13 2011-03-10 Merck Sharp & Dohme Corp. Tricyclic anilide spirohydantoin CGRP receptor antagonists
US8003792B2 (en) * 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
CA2629406A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
EP1951042B1 (de) 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Spirolactam tricyclische cgrp-rezeptor-antagonisten
EP1954135B1 (de) * 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Spirolactam-aryl cgrp-rezeptor-antagonisten
US7968540B2 (en) 2005-11-18 2011-06-28 Merck Sharp & Dohme Corp. Spirohydantoin tricyclic CGRP receptor antagonists
WO2007120589A2 (en) * 2006-04-10 2007-10-25 Merck & Co., Inc. Process for the preparation of caprolactam cgrp antagonist intermediate
EP2013213B1 (de) 2006-05-02 2011-07-27 Bristol-Myers Squibb Company Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten.
US7470680B2 (en) * 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
WO2007133491A1 (en) * 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
JP5511379B2 (ja) * 2006-07-21 2014-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Cgrpレセプターアンタゴニスト
US7951795B2 (en) * 2006-12-08 2011-05-31 Merck Sharp & Dohme Corp. Constrained spirocyclic compounds as CGRP receptor antagonists
US8372859B2 (en) * 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
CA2683745A1 (en) * 2007-04-16 2008-10-30 Merck & Co., Inc. Bicyclic anilide heterocyclic cgrp receptor antagonists
WO2008130524A1 (en) * 2007-04-16 2008-10-30 Merck & Co., Inc. Aryl heterocyclic cgrp receptor antagonists
CA2689217C (en) * 2007-06-05 2016-02-16 Merck & Co., Inc. Carboxamide heterocyclic cgrp receptor antagonists
US8163752B2 (en) * 2007-06-07 2012-04-24 Merck, Sharp & Dohme Corp. Tricyclic anilide heterocyclic CGRP receptor antagonists
JP2011512410A (ja) * 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンcgrp受容体アンタゴニスト
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CA2734168A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. 3- and 6-quinolines with n-attached heterocyclic cgrp receptor antagonists
TWI501968B (zh) * 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑
WO2012064911A1 (en) * 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane cgrp receptor antagonists
WO2012087777A1 (en) 2010-12-22 2012-06-28 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide cgrp receptor antagonists
EP2654423B1 (de) * 2010-12-22 2016-12-07 Merck Sharp & Dohme Corp. Kondensierte heterocyclische azaindan-carboxamid-cgrp-rezeptorantagonisten
EP2554539B1 (de) 2011-08-02 2014-12-10 Universität Potsdam Verfahren zur Herstellung von gamma-Spirolactamen aus zyklischen ungesättigten Carbonsäuren
CA2870019C (en) 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
WO2013169565A1 (en) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
EP2846799B1 (de) 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam-cgrp-rezeptorantagonisten
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
WO2013169563A1 (en) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
WO2015038736A2 (en) * 2013-09-16 2015-03-19 Merck Sharp & Dohme Corp. Formulations for cgrp receptor antagonists
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
TW201718574A (zh) * 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
AU2017290362B2 (en) 2016-07-01 2021-08-05 Pharmacosmos Holding A/S Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ. ホフマン-ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3366286A1 (de) 2017-02-22 2018-08-29 Johannes Keller Verbindungen zur behandlung von sepsis
EP3645001B1 (de) 2017-06-29 2024-07-03 G1 Therapeutics, Inc. Morphe formen von git38 und herstellungsverfahren dafür
EP3781571B1 (de) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-carboxamid-derivate und ähnliche verbindungen als rip1 kinase inhibitoren zur behandlung von z.b. reizdarmsyndrom (rds)
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
KR102962306B1 (ko) 2018-08-24 2026-05-08 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
EP4463229A1 (de) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Kristalline formen von (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b! [l,4)oxazepin-3-yl)-4h-1,2,4-triazol-3-carboxamid
WO2024134683A1 (en) * 2022-12-21 2024-06-27 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of intermediate compounds used in the treatment of migraine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307108A (en) * 1979-12-26 1981-12-22 Pfizer Inc. Method for lowering sorbitol levels using spiro-imides
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
WO2004087648A2 (en) * 2003-03-12 2004-10-14 Sun Pharmaceutical Industries Limited Stabilized phenytoin containing composition
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
EP1606286B1 (de) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten
US8003792B2 (en) * 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists

Also Published As

Publication number Publication date
AU2005285197A1 (en) 2006-03-23
AU2005285197B2 (en) 2011-03-10
DE602005020655D1 (de) 2010-05-27
CA2579840A1 (en) 2006-03-23
JP5039553B2 (ja) 2012-10-03
CN101448821A (zh) 2009-06-03
US7390798B2 (en) 2008-06-24
EP1796678A2 (de) 2007-06-20
EP1796678A4 (de) 2009-09-02
WO2006031606A2 (en) 2006-03-23
CA2579840C (en) 2012-03-20
CN101448821B (zh) 2013-03-27
US20070293470A1 (en) 2007-12-20
WO2006031606A3 (en) 2007-08-09
JP2008512480A (ja) 2008-04-24
EP1796678B1 (de) 2010-04-14

Similar Documents

Publication Publication Date Title
EP1796678A4 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
TW200505903A (en) CGRP receptor antagonists
NO20072435L (no) CGRP-reseptorantagonister
ATE466860T1 (de) Cgrp-rezeptorantagonisten
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
EP1605936A4 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
ATE535514T1 (de) Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
EP1641423A4 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
ATE537170T1 (de) Cgrp-rezeptorantagonisten
EP1606286A4 (de) Benzodiazepinspirohydantoine als cgrp-rezeptorantagonisten
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
WO2006029153A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists
ATE464305T1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
EP1794133A4 (de) Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
WO2006041830A3 (en) Cgrp receptor antagonists
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
ATE466853T1 (de) Cgrp-rezeptorantagonisten
DE60313898D1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties